SEP
PCRX icon

Signature Equity Partners’s Pacira BioSciences PCRX Stock Holding History

Signature Equity Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-559
Closed -$12.6K – 1670
2026
Q1 		$12.6K Sell
559
-165
-23% -$3.67K 0.01% 757
2025
Q4 		$18.7K Buy
+724
New +$17.2K 0.01% 642

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's PCRX Position: Q2 2026 in Review

Signature Equity Partners sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 559 shares — an estimated $12.6K sold.

Signature Equity Partners first reported a position in PCRX in Q4 2025 and held it in 2 quarters. The position peaked at $18.7K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Signature Equity Partners reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Signature Equity Partners sold 559 Pacira BioSciences shares in Q2 2026, an estimated $12.6K.
  • Signature Equity Partners first reported a position in Pacira BioSciences in Q4 2025 and held it in 2 quarters.
  • Signature Equity Partners's Pacira BioSciences position peaked at $18.7K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.